Document is current
Any future updates will be listed below
-
Authors
Merz, Maximilian https://orcid.org/0000-0002-2805-5973
Merz, Almuth Maria Anni
Wang, Jie
Wei, Lei https://orcid.org/0000-0002-1881-8666
Hu, Qiang https://orcid.org/0000-0002-4090-5539
Hutson, Nicholas
Rondeau, Cherie
Celotto, Kimberly
Belal, Ahmed
Alberico, Ronald
Block, AnneMarie W.
Mohammadpour, Hemn
Wallace, Paul K.
Tario, Joseph
Luce, Jesse
Glenn, Sean T.
Singh, Prashant
Herr, Megan M. https://orcid.org/0000-0001-5768-9396
Hahn, Theresa https://orcid.org/0000-0002-3835-8855
Samur, Mehmet https://orcid.org/0000-0002-9978-5682
Munshi, Nikhil https://orcid.org/0000-0002-7344-9795
Liu, Song
McCarthy, Philip L.
Hillengass, Jens https://orcid.org/0000-0002-1778-0010
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (Mildred Scheel grant)
- License Information
-
More Information
Article History
Received: 13 January 2021
Accepted: 14 January 2022
First Online: 10 February 2022
Competing interests
: P.L.M.: Advisory Board/Consulting: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, Takeda; Honoraria: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, Takeda. JH: Advisory Boards/ Honoraria: Adaptive, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncotracker, Oncopeptide, Skyline, Takeda. M.M.: Advisory Boards/ Honoraria: Amgen, BMS, Celgene and Takeda. Institutional Research Support: Celgene to P.L.M. and M.M. The remaining authors declare no conflict of interest.
